Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 292 free, full-text research articles on human participants. First 3 results:

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
 

Author(s): Erica J Childs, Evelina Mocci, Daniele Campa, Paige M Bracci, Steven Gallinger, Michael Goggins, Donghui Li, Rachel E Neale, Sara H Olson, Ghislaine Scelo, Laufey T Amundadottir, William R Bamlet, Maarten F Bijlsma, Amanda Blackford, Michael Borges, Paul Brennan, Hermann Brenner, H Bas Bueno-de-Mesquita, Federico Canzian, Gabriele Capurso, Giulia M Cavestro, Kari G Chaffee, Stephen J Chanock, Sean P Cleary, Michelle Cotterchio, Lenka Foretova, Charles Fuchs, Niccola Funel, Maria Gazouli, Manal Hassan, Joseph M Herman, Ivana Holcatova, Elizabeth A Holly, Robert N Hoover, Rayjean J Hung, Vladimir Janout, Timothy J Key, Juozas Kupcinskas, Robert C Kurtz, Stefano Landi, Lingeng Lu, Ewa Malecka-Panas, Andrea Mambrini, Beatrice Mohelnikova-Duchonova, John P Neoptolemos, Ann L Oberg, Irene Orlow, Claudio Pasquali, Raffaele Pezzilli, Cosmeri Rizzato, Amethyst Saldia, Aldo Scarpa, Rachael Z Stolzenberg-Solomon, Oliver Strobel, Francesca Tavano, Yogesh K Vashist, Pavel Vodicka, Brian M Wolpin, Herbert Yu, Gloria M Petersen, Harvey A Risch, Alison P Klein

Journal: Nat. Genet.. 2015 Aug;47(8):911-6.

 

Pancreatic cancer is the fourth leading cause of cancer death in the developed world. Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM, PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A and mismatch-repair genes and low-penetrance loci are associated with increased ...

Last Updated: 29 Jul 2015

Go To URL
Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy.
 

Author(s): Christian Stoy, Aishwarya Sundaram, Marcos Rios Garcia, Xiaoyue Wang, Oksana Seibert, Annika Zota, Susann Wendler, David Männle, Ulf Hinz, Carsten Sticht, Maria Muciek, Norbert Gretz, Adam J Rose, Vera Greiner, Thomas G Hofmann, Andrea Bauer, Jörg Hoheisel, Mauricio Berriel Diaz, Matthias M Gaida, Jens Werner, Tobias Schafmeier, Oliver Strobel, Stephan Herzig

Journal:

 

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer fatalities in Western societies, characterized by high metastatic potential and resistance to chemotherapy. Critical molecular mechanisms of these phenotypical features still remain unknown, thus hampering ...

Last Updated: 5 Aug 2015

Go To URL
Mucin 1 Regulates Cox-2 Gene in Pancreatic Cancer.
 

Author(s): Sritama Nath, Lopamudra Das Roy, Priyanka Grover, Shanti Rao, Pinku Mukherjee

Journal: Pancreas. 2015 Aug;44(6):909-17.

 

Eighty percent of pancreatic ductal adenocarcinomas (PDAs) overexpress mucin 1 (MUC1), a transmembrane mucin glycoprotein. MUC1(high) PDA patients also express high levels of cyclooxygenase 2 (COX-2) and show poor prognosis. The cytoplasmic tail of MUC1 (MUC1-CT) partakes in oncogenic ...

Last Updated: 13 Jul 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 6 free, full-text review articles on human participants. First 3 results:

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
 

Author(s): Doudou Li, Changhao Chen, Yu Zhou, Rufu Chen, Xinxiang Fan, Zhuofei Bi, Zhihua Li, Yimin Liu

Journal: Medicine (Baltimore). 2015 Sep;94(35):e1345.

 

Several reports suggest that gemcitabine (GEM) plus S-1 combination (GS) is associated to prolong the survival in patients with unresectable pancreatic cancer (PC). We conducted a systemic review and meta-analysis of studies comparing the safety and efficacy of GS versus GEM.Summary ...

Last Updated: 4 Sep 2015

Go To URL
S-1 in the treatment of pancreatic cancer.
 

Author(s): Kentaro Sudo, Kazuyoshi Nakamura, Taketo Yamaguchi

Journal: World J. Gastroenterol.. 2014 Nov;20(41):15110-8.

 

S-1 is an oral 5-fluorouracil (5-FU) prodrug, which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase, the key enzyme of 5-FU catabolism. Recently, two important studies on the clinical use of S-1 for pancreatic cancer have been reported ...

Last Updated: 11 Nov 2014

Go To URL
Involvement of substance P and the NK-1 receptor in pancreatic cancer.
 

Author(s): Miguel Muñoz, Rafael Coveñas

Journal: World J. Gastroenterol.. 2014 Mar;20(9):2321-34.

 

Pancreatic cancer is the fourth leading cause of cancer related-death for both men and women and the 1- and 5-year relative survival rates are 25% and 6%, respectively. Thus, it is urgent to investigate new antitumor drugs to improve the survival of pancreatic cancer patients. The ...

Last Updated: 7 Mar 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
 

Status: Recruiting

Condition Summary: Metastatic Pancreatic Cancer; ERCC1

 

Last Updated: 30 Jan 2012

Go to URL
Pancreatic Cancer Early Detection Program
 

Status: Recruiting

Condition Summary: Pancreatic Cancer; Pancreas Cancer; Pancreatic Adenocarcinoma; Familial Pancreatic Cancer; BRCA 1/2; HNPCC; Lynch Syndrome; Hereditary Pancreatitis; FAMMM; Familial Atypical Multiple Mole Melanoma; Peutz Jeghers Syndrome

 

Last Updated: 30 Jul 2014

Go to URL
Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer
 

Status: Recruiting

Condition Summary: Advanced Pancreatic Cancer

 

Last Updated: 12 Aug 2014

Go to URL